ライフサイエンスコーパス: indocyanine

1 d structure of pentamethine and heptamethine indocyanines.

2 luster headache (n = 5) using fluorescein or indocyanine angiography.

3 y (OCT), en-face OCT, OCTA, fluorescence and indocyanine angiography.

4 ode tracer consisting of the fluorescent dye indocyanine green (ICG) and (99m)Tc-nanocolloid with the

5 Indocyanine green (ICG) and epirubicin (EPI) could co-se

6 in infrared reflectance (IR) photographs and indocyanine green (ICG) angiograms.

7 orescence (FAF), and fluorescein angiography/indocyanine green (ICG) angiography findings, of patient

8 glycated chitosan (GC) as immunoadjuvant and indocyanine green (ICG) as laser-absorbing dye have show

9 infrared (NIR) range, clinical potential of indocyanine green (ICG) as PT is limited by its short ha

10 Liver function was assessed by clearance of indocyanine green (ICG) at 4, 20 and 28 hours.

11 ood flow and function were determined by the indocyanine green (ICG) clearance test.

12 The near-infrared dye indocyanine green (ICG) could serve as a basis for such

13 otic shock technique was used to encapsulate indocyanine green (ICG) dye in erythrocyte ghost cells a

14 /J mice was induced by combined injection of indocyanine green (ICG) dye into the anterior chamber an

15 espectively tracked iron oxide particles and indocyanine green (ICG) encapsulated in the NPs as trace

16 ogenase (LDH) activity, bile production, and indocyanine green (ICG) extraction.

17 tomography (DOT) after the administration of indocyanine green (ICG) for contrast enhancement.

18 Hyperfluorescent cells labeled with indocyanine green (ICG) have been observed in retinal an

19 I) using an intraoperative injection of free indocyanine green (ICG) in the detection of peritoneal m

20 sed signal strength by as much as 36.3%, and indocyanine green (ICG) increased signal magnitudes by a

21 ceived 0.5 mg per kilogram of body weight of indocyanine green (ICG) intravenously 24 hours prior to

22 on and lower autofluorescence; however, only indocyanine green (ICG) is clinically approved.

23 -enhanced Raman scattering (SERS) studies on indocyanine green (ICG) on colloidal silver and gold and

24 The data indicated that (1) formulated indocyanine green (ICG) readily penetrated hyperkeratoti

25 study was to evaluate the performance of the indocyanine green (ICG) retention test as a noninvasive

26 Both indocyanine green (ICG) solution and TA suspension, at 5

27 Indocyanine green (ICG) was administered intravenously 1

28 as been uniquely accomplished with NIR using indocyanine green (ICG), a nonspecific dye that has comp

29 Here we report that indocyanine green (ICG), an infrared fluorescent dye wit

30 lowly releasing a pressurized cuff occluding indocyanine green (ICG), demonstrated an increase in ves

31 tein (GFP), tricarbocyanine 5.5 (Cy5.5), and indocyanine green (ICG), filters were selected to allow

32 e well-known and widely used fluorescent dye indocyanine green (ICG), which has FDA approval, exhibit

33 ntraprostatic injection of the hybrid tracer indocyanine green (ICG)-(99m)Tc-nanocolloid enables both

34 The fluorophore outperformed indocyanine green (ICG)-a clinically approved NIR-I dye-

35 rs, and 24 hours after systemic injection of indocyanine green (ICG).

36 ugated with a near-infrared fluorescent dye [indocyanine green (ICG)] targets low extracellular pH, a

37 Fluorescein (FA) and indocyanine green (ICGA) angiography (Heidelberg Spectra

38 Indocyanine green and BPD angiography were performed in

39 ting (electrophysiology, fundus photography, indocyanine green and fluorescein angiography, and magne

40 mography (OCT), fundus autofluorescence, and indocyanine green and fluorescein angiography, was avail

41 nusoidal endothelial cells were evaluated by indocyanine green and hyaluronic acid uptake.

42 eceived a standardised cervical injection of indocyanine green and sentinel-lymph-node mapping follow

43 he success rate of laser treatment guided by indocyanine green angiographic findings can vary conside

44 in an area of hypofluorescence on late-phase indocyanine green angiographic images.

45 ng color fundus photography, fluorescein and indocyanine green angiographies, spectral-domain optical

46 Indocyanine green angiography (ICG) was used to identify

47 s photography, fluorescein angiography (FA), indocyanine green angiography (ICG), optical coherence t

48 To investigate indocyanine green angiography (ICGA) findings in patient

49 Concurrent fluorescein angiography (FA) and indocyanine green angiography (ICGA) images were used to

50 escence (FAF), fluorescein angiography (FA), indocyanine green angiography (ICGA), and SD-OCT were pe

51 hy (OCTA), fluorescein angiography (FA), and indocyanine green angiography (ICGA), and the images fro

52 imultaneous fluorescein angiography (FA) and indocyanine green angiography (ICGA), enhanced-depth ima

53 eflectance, fundus autofluorescence imaging, indocyanine green angiography (ICGA), preferential hyper

54 obtained using fluorescein angiography (FA), indocyanine green angiography (ICGA), structural optical

55 rate vitritis, and hypocyanescent lesions on indocyanine green angiography (ICGA).

56 CT, OCT-A, fluorescein angiography (FA), and indocyanine green angiography (ICGA).

57 Baseline fluorescein angiography and indocyanine green angiography also were performed.

58 Advances in imaging, particularly in indocyanine green angiography and optical coherence tomo

59 patients with extrafoveal PCV, confirmed on indocyanine green angiography and treated with argon las

60 In dry macular degeneration, indocyanine green angiography appears to add clinically

61 In certain circumstances, indocyanine green angiography can be valuable in detecti

62 Indocyanine green angiography confirmed choroidal inflam

63 vidence of retinal vasculitis or papillitis, indocyanine green angiography evidence of active choroid

64 Indocyanine green angiography has allowed us to look at

65 For the past year, indocyanine green angiography has been applied to evalua

66 sarcoidosis in intraocular inflammation, and indocyanine green angiography has clarified choroidal in

67 The relative safety of indocyanine green angiography has contributed to its con

68 developments in the clinical application of indocyanine green angiography have mainly concerned refi

69 ptical coherence tomography, fluorescein and indocyanine green angiography in a 66 years old man suff

70 rrelated with the polypoidal lesions seen on indocyanine green angiography in all PCV eyes.

71 erns of abnormal hyperfluorescence seen with indocyanine green angiography in eyes with both wet and

72 al coherence tomography, and fluorescein and indocyanine green angiography in patients suspected of h

73 udies demonstrating choroidal involvement by indocyanine green angiography in patients with HTLV-1-as

74 Indocyanine green angiography is improving our understan

75 Indocyanine green angiography revealed the presence of c

76 d 1970s, the introduction of fluorescein and indocyanine green angiography revolutionized our ability

77 was confirmed by fluorescein angiography and indocyanine green angiography testing.

78 nding hypofluorescence in 100% of cases when indocyanine green angiography was performed.

79 us examination, fluorescein angiography, and indocyanine green angiography were included.

80 olor images, and fluorescein angiography and indocyanine green angiography were measured before and a

81 Fluorescein and indocyanine green angiography were performed in patients

82 FA), optical coherence tomography (OCT), and indocyanine green angiography were performed.

83 dalities such as magnetic resonance imaging, indocyanine green angiography, and digital image analysi

84 as ultrasonography, fluorescein angiography, indocyanine green angiography, and magnetic resonance im

85 rements, fundus photography, fluorescein and indocyanine green angiography, and microperimetry.

86 uorescence imaging, fluorescein angiography, indocyanine green angiography, and optical coherence tom

87 Ophthalmic CT, fluorescein angiography, indocyanine green angiography, and others are demonstrat

88 ser ophthalmoscopy, fluorescein angiography, indocyanine green angiography, and spectral-domain optic

89 ncluding fundus photography, fluorescein and indocyanine green angiography, fundus autofluorescence i

90 color photography, fluorescein angiography, indocyanine green angiography, near-infrared reflectance

91 amination including fluorescein angiography, indocyanine green angiography, spectral-domain optical c

92 for fluorescence, including fluorescein and indocyanine green angiography.

93 lar evaluation by a simultaneous fluorescein/indocyanine green angiography.

94 good correlation with lesions identified on indocyanine green angiography.

95 t, and regression of polypoidal complexes on indocyanine green angiography.

96 omography, fluorescein angiography (FA), and indocyanine green angiography.

97 erence tomography (OCT), and fluorescein and indocyanine green angiography.

98 Trypan Blue and Indocyanine Green appear to be most effective in stainin

99 Intraoperative visualization of the SLN by indocyanine green before skin incision was successful in

100 tly faster lymphatic drainage as measured by indocyanine green clearance and increased lymphatic vess

101 llular function was determined by an in vivo indocyanine green clearance technique.

102 Indocyanine green clearance was measured in two animals

103 lationship between the increments in VO2 and indocyanine green clearance was observed (r2 = .21; p =

104 e maximal velocity and efficiency of in vivo indocyanine green clearance) was determined and hepatocy

105 l velocity and overall efficiency of in vivo indocyanine green clearance) were assessed at 24 hours a

106 ximum velocity and the overall efficiency of indocyanine green clearance) were determined at 4 hrs af

107 ximum velocity and the overall efficiency of indocyanine green clearance) were determined.

108 Indocyanine green clearance, as determined by a fiberopt

109 A noninvasive measurement of indocyanine green clearance, the plasma disappearance ra

110 velocity and transport efficiency of in vivo indocyanine green clearance.

111 , N-acetylcysteine elicits an improvement in indocyanine green clearance.

112 ut not VO2) and a nonsignificant increase in indocyanine green clearance.

113 The number of new indications for indocyanine green continues to increase, including innov

114 ulating blood volume were assessed using the indocyanine green dilution technique and a left ventricu

115 When indocyanine green dosages were 10 microg or higher, lymp

116 Indocyanine green dye (0.08 mg/ml in D5W) was injected s

117 EGF-Cy5.5, but not Cy5.5 or indocyanine green dye (ICG), bound to MDA-MB-468 cells.

118 ith 50- to 100-fold greater concentration of Indocyanine Green dye over background levels.

119 f the PKWS subject that transported injected indocyanine green dye to the inguinal lymph node and dra

120 Near-infrared reflectance measurements of indocyanine green dye uptake indicated that there were n

121 Indocyanine green dye was used as a nonspecific control

122 ining of the internal limiting membrane with indocyanine green dye, and variations in the length of p

123 Indocyanine green elimination constants (K(ICG)) were me

124 Based upon Indocyanine Green encapsulation within the nanoparticles

125 Mean rates of bile flow, biliary indocyanine green excretion, and bile acid flux were sig

126 Indocyanine green fluorescence imaging is a surgical too

127 ependent or that refine the existing method: indocyanine green fluorescence, contrast-enhanced ultras

128 cutaneous melanoma on the trunk), the use of indocyanine green for SLN detection is severely limited

129 TATION: Sentinel lymph nodes identified with indocyanine green have a high degree of diagnostic accur

130 direct cannulation, perivascular flowprobe, indocyanine green imaging, and functional magnetic reson

131 l subcutaneous injections of 0.31-100 microg indocyanine green in the breast in this IRB-approved, HI

132 Hepatic blood flow was determined by indocyanine green infusion.

133 l retrospective studies, the fluorescent dye indocyanine green is considered a possible alternative t

134 Lymph imaging consistently failed with indocyanine green microdosages between 0.31 and 0.77 mic

135 ontrast-enhanced magnetic resonance imaging, indocyanine green near-infrared imaging, and intravital

136 In patients who received 10 microg of indocyanine green or more, a weak negative correlation b

137 tic function (transpulmonary thermodilution, indocyanine green plasma disappearance rate [ICG-PDR]) w

138 Immediately after administration, indocyanine green provided a significant increase in the

139 /-0.5 vs. 33.2+/-1.7 microg/min/g liver) and indocyanine green secretion (11.7+/-1.7 vs. 21.2+/-2.1 A

140 usion model, lactate dehydrogenase activity, indocyanine green secretion, and portal pressure values

141 antitative liver function tests, such as the indocyanine green test and galactose elimination capacit

142 , and an ex vivo spectrophotometric assay of indocyanine green uptake (1.87-fold increase in normaliz

143 ated similar hyaluronic acid uptake, whereas indocyanine green uptake was markedly impaired in the hy

144 perfusion) and in vivo (hyaluronic acid and indocyanine green uptake, arterial ketone body ratio, or

145 At anesthesia induction, indocyanine green was injected intravenously.

146 that contained micromolar concentrations of indocyanine green with 1:0 and 100:1 target-to-backgroun

147 of the feature sizes of a common NIR I dye (indocyanine green) showed a more rapid loss of feature c

148 ation of theranostic agents (doxorubicin and indocyanine green).

149 uated the in vivo uptake of hyaluronic acid, indocyanine green, and radio-labeled sulphur colloid to

150 Using relatively high doses of indocyanine green, long-term enhanced fluorescence of ar

151 gent mixture composed of fluorescein sodium, indocyanine green, PCM102, and PCM107 and imaged with a

152 The clinically applied hybrid tracer indocyanine green-(99m)Tc-nanocolloid enables combined r

153 e cancer during an SN biopsy procedure using indocyanine green-(99m)Tc-nanocolloid.

154 At the time of reperfusion, indocyanine green-based in vivo imaging showed that CD47

155 Administration-cleared devices designed for indocyanine green-based perfusion imaging to identify ca

156 al nonimmobilized limb, confirmed by in vivo indocyanine green-enhanced NIR optical imaging (3.86-fol

157 of muscle damage was obtained using in vivo indocyanine green-enhanced NIR optical imaging, magnetic

158 Fusion of indocyanine green-enhanced optical imaging and radiograp

159 Indocyanine green-enhanced optical imaging is a clinical

160 Fusion of indocyanine green-enhanced optical imaging scans with ra

161 following intravenous injection of 10 mg/kg indocyanine green.

162 stic signals compared with the commonly used indocyanine green.

163 t encapsulate the near infrared chromophore, indocyanine green.

164 Indocyanine-green angiography (ICG-A) may be considered

165 tofluorescence, fluorescein angiography, and indocyanine-green angiography (ICGA).

166 By the direct Fick, or the indocyanine-green or both, methods and by renal clearanc

167 Values of bile production, indocyanine secretion, and cellular damages were compara